scholarly journals Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome

2014 ◽  
Vol 8 (1) ◽  
pp. 47-54 ◽  
Author(s):  
PIOTR RUTKOWSKI ◽  
ALEKSANDRA GOS ◽  
MONIKA JURKOWSKA ◽  
TOMASZ ŚWITAJ ◽  
WIRGINIUSZ DZIEWIRSKI ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Cutaneous Melanoma ◽  
Clinical Stage ◽  
Clinicopathological Features ◽  
Stage Iii ◽  
Molecular Alterations

The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Artur Kowalik ◽  
Monika Jurkowska ◽  
Ewa Mierzejewska ◽  
Iwona Ługowska ◽  
Aleksandra Gos ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Kinase Inhibitors ◽  
Clinical Stage ◽  
Stage Iii ◽  
Prognostic Role ◽  
Wnt Pathways

scholarly journals Comparison of non-schistosomal colorectal cancer and schistosomal colorectal cancer

2020 ◽  
Author(s):  
Weixia Wang ◽  
Kui Lu ◽  
Limei Wang ◽  
Hongyan Jing ◽  
Weiyu Pan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Clinical Stage ◽  
Clinicopathological Features ◽  
Stage Iii ◽  
Prognostic Role ◽  
Node Metastasis ◽  
Significant Difference ◽  
Cox Proportional Hazard Regression

Abstract Aim The purpose of this study was to compare clinicopathological features of patients with non-schistosomal and schistosomal colorectal cancer to explore the prognostic role of schistosoma infection in colorectal cancer(CRC). Methods 354 cases of CRC were retrospectively analyzed in a tissue microarray format. Survival curves were constructed by using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazard regression models were performed to identify associations with outcome variables. Results Patients with schistosomiasis (CRC-S) were significantly older ( P <0.001) and were mostly in stage III and IV tumors ( P <0.001) than patients without schistosomiasis (CRC-NS). However, there were no significant difference between CRC-S and CRC-NS patients in other clinicopathological features. Overall, CRC-S patients were associated with adverse overall survival upon K-M analysis ( P =0.0239). By univariate and multivariate analysis, CRC-S patients were significantly correlated with OS ( P =0.041), but it was not an independent prognostic factor. In addition, age( P =0.013), gender ( P =0.008), tumor differentiation ( P =0.018) and invasive depth ( P =0.013) were all independent predictors. When patients were stratified according to clinical stage and lymph node metastasis state, the prognostic role was not consistent. In patients with stage III-IV tumors and with lymph node metastasis, schistosomiasis, gender and invasive depth were independent predictors, but not in patients with stage I-II tumors and in patients without lymph node metastasis. Conclusion Schistosomiasis is an unfavorable factor for OS and could be considered to refine risk stratification and provide better risk-oriented treatment for CRC patients with different clinical stage or lymph node metastasis state.

scholarly journals Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians

2020 ◽  
Vol 9 (9) ◽  
pp. 2996
Author(s):  
Aneta M. Borkowska ◽  
Anna Szumera-Ciećkiewicz ◽  
Mateusz J. Spałek ◽  
Paweł Teterycz ◽  
Anna M. Czarnecka ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cutaneous Melanoma ◽  
Clinical Stage ◽  
Lymph Node Biopsy ◽  
Clinicopathological Features ◽  
Primary Cutaneous Melanoma

Background: Cutaneous melanomas located on the acral part of extremities (hand and foot melanoma; HFM) comprise a rare group within all melanomas in Caucasians. HFM is associated with a poor prognosis. We aimed to evaluate clinicopathological features, long-term outcomes, and prognostic factors in primary HFM in Caucasians. Methods: Medical records of all consecutive patients treated between 1997 and 2014 were revised. Patients were diagnosed with primary cutaneous melanoma at I-II clinical stage, and sentinel lymph node biopsy was conducted. The analysis was performed to define the clinicopathological factors influencing outcomes in the HFM and subungual cohort. Among 2537 consecutive patients diagnosed with primary cutaneous melanoma, 247 cases of HFM (9.7%) were found, with a median follow-up time of 7.8 years. Results: Median primary tumor Breslow thickness in subungual melanomas and HFMs was 4.0 mm and 3.3 mm, respectively, significantly higher than in the entire population (median 2.2 mm; p < 0.01). In the HFM group, 37.6% of tumors were ulcerated. Metastases to sentinel lymph node (SLN) were found in 28.3% of HFMs. The 10-year overall survival rate in the HFM group and subungual melanomas was 48.1% and 49.3%, respectively, compared to 63.0% in non-HFM melanomas. Conclusions: Our results confirm that patients with HFMs display worse overall survival compared to the entire melanoma population, with male gender and positive SLN biopsy status acting as independent negative prognostic factors.

Correlations of molecular alterations in clinical stage III cutaneous melanoma with clinical-pathological features and patients outcome.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8548-8548 ◽  
Author(s):  
Piotr Rutkowski ◽  
Monika Jurkowska ◽  
Aleksandra Gos ◽  
Andrzej Tysarowski ◽  
Wanda Michej ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Primary Tumor ◽  
Clinical Stage ◽  
Stage Iii ◽  
Nodal Metastases ◽  
Clinicopathologic Features ◽  
Wild Type ◽  
Tumor Excision ◽  
Mutational Status ◽  
Melanoma Patients

8548 Background: To evaluate frequency and type of oncogenic BRAF/NRAS mutations in cutaneous melanoma with clinically detected nodal metastases (stage IIIB,C) in relation to clinicopathologic features and outcome. Methods: We analyzed 221 patients after therapeutic lymphadenectomy-LND (1995-2010) not treated with tyrosine kinase inhibitors and performed molecular characterization of nodal metastases in terms of BRAF/NRAS genes (analyzed by sequencing of respective coding sequences). Median follow-up time was 53 months. Results: BRAF mutations were detected in 139 (63%) cases (127–V600E, 8–V600K, 4-others), mutually exclusive NRAS mutations in 35(15.8%) cases (mainly Q61R and Q61K). BRAF mutation presence correlated with patients' younger age(median 52 vs 60 years for BRAF+ vs. BRAF-, p<0.05), metastases in axillary basin (p<0.05) and less involved nodes (median 3 vs. 4; p<0.05). 5-year overall survival (OS) was 35% and 45% (calculated from date of LND and primary tumor excision, respectively); 5-year recurrence-free survival RFS (from LND) – 29%. We have not found correlation between mutational status and RFS or OS (calculated from date of LND and primary tumor excision) – for BRAF mutated-melanomas prognosis was the same as wild-type melanoma patients(p=0.26) with even trend for better OS for non-V600E mutants. Negative prognostic factors (in univariate and multivariate analysis) for OS and RFS were: male gender (p<0.01), metastatic lymph nodes>1 (p<0.001), nodal metastases extracapsular extension (p<0.001). The interval from diagnosis of first-ever melanoma to regional nodal metastasis (median-10 months) was not significantly different between BRAF-mutant and BRAF wild-type patients (p=0.29). Conclusions: BRAF/NRAS mutational status is not prognostic marker in stage III melanoma patients with macroscopic nodal involvement, what may have implication for potential adjuvant therapy. BRAF status had no impact on disease-free interval from diagnosis of primary melanoma to nodal metastases. Our first-ever comprehensive molecular analysis of clinical stage III melanomas revealed that BRAF-mutants show characteristic clinicopathologic features.

scholarly journals Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors

2013 ◽  
Vol 11 (1) ◽  
pp. 36 ◽  
Author(s):  
Nicola Mozzillo ◽  
Corrado Caracò ◽  
Ugo Marone ◽  
Gianluca Di Monta ◽  
Anna Crispo ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Lymph Node ◽  
Clinical Outcome ◽  
Lymph Node Dissection ◽  
Cutaneous Melanoma ◽  
Stage Iii ◽  
Node Dissection

scholarly journals Tumor Tissue MIR92a and Plasma MIRs21 and 29a as Predictive Biomarkers Associated with Clinicopathological Features and Surgical Resection in a Prospective Study on Colorectal Cancer Patients

2020 ◽  
Vol 9 (8) ◽  
pp. 2509
Author(s):  
Masahiro Fukada ◽  
Nobuhisa Matsuhashi ◽  
Takao Takahashi ◽  
Nobuhiko Sugito ◽  
Kazuki Heishima ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prospective Study ◽  
Surgical Resection ◽  
Tumor Tissue ◽  
Lymphatic Invasion ◽  
Clinicopathological Features ◽  
Stage Iii ◽  
Sample Type ◽  
Significant Difference ◽  
A Prospective Study

Cancer-related microRNAs (miRNAs) are emerging as non-invasive biomarkers for colorectal cancer (CRC). This study aimed to analyze the correlation between the levels of tissue and plasma miRNAs and clinicopathological characteristics and surgical resection. This study was a prospective study of CRC patients who underwent surgery. Forty-four sample pairs of tissue and plasma were analyzed. The miRNA levels were evaluated by RT-qPCR. The level of tumor tissue MIR92a showed a significant difference in CRC with lymph node metastasis, stage ≥ III, and high lymphatic invasion. In preoperative plasma, there were significant differences in CRC with stage ≥ III (MIR29a) and perineural invasion (MIR21). In multivariate analysis of lymphatic invasion, the levels of both preoperative plasma MIR29a and tumor tissue MIR92a showed significant differences. Furthermore, in cases with higher plasma miRNA level, the levels of plasma MIRs21 and 29a were significantly decreased after the operation. In this study, there were significant differences in miRNAs levels with respect to the sample type, clinicopathological features, and surgical resection. The levels of tumor tissue MIR92a and preoperative plasma MIR29a may have the potential as a biomarker for prognosis. The plasma MIRs21 and 29a level has the potential to be a predictive biomarker for treatment efficacy.

Sign in / Sign up

Export Citation Format

Share Document